HIGHLIGHTS
- who: Dnyaneshwar Kalyane and collaborators from the National Institute of Pharmaceutical Education and Research (NIPER), Ahmedabad, An Institute of National Government of India, Gandhinagar, India have published the paper: CD44-Receptor Targeted Gold-Doxorubicin Nanocomposite for Pulsatile Chemo-Photothermal Therapy of Triple-Negative Breast Cancer Cells, in the Journal: Pharmaceutics 2022, 2734 of /2022/
- what: This study reports the (T GNCDOX) for pulsatile chemo-photothermal therapy of triple-negative breast cancer (TNBC). This investigation explores laser-responsive gold nanocomposite with cancer cell-specific CD44-receptor targeting efficiency (T GNC-DOX) to mediate chemo-photothermal ablation . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.